970 related articles for article (PubMed ID: 8392394)
1. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
Mortensen BM; Gautvik KM; Gordeladze JO
Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
[TBL] [Abstract][Full Text] [Related]
2. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
3. Relationship between circulating vitamin D3 metabolites and prolactin or growth hormone levels in rat.
Mortensen B; Gordeladze JO; Haug E; Schjerven L; Gautvik KM
Pharmacol Toxicol; 1993 Mar; 72(3):188-93. PubMed ID: 8516267
[TBL] [Abstract][Full Text] [Related]
4. Human parathyroid hormone (1-34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3.
Gunness-Hey M; Hock JM; Gera I; Fonseca J; Poser J; Bevan J; Raisz LG
Calcif Tissue Int; 1986 Apr; 38(4):234-8. PubMed ID: 3085902
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone, calcitonin and vitamin D metabolites in beta-thalassaemia major.
Zamboni G; Marradi P; Tagliaro F; Dorizzi R; Tatò L
Eur J Pediatr; 1986 Apr; 145(1-2):133-6. PubMed ID: 3015625
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D3 analogs and salmon calcitonin partially reverse the development of renal osteodystrophy in rats.
Jablonski G; Mortensen BM; Klem KH; Mosekilde L; Danielsen CC; Gordeladze JO
Calcif Tissue Int; 1995 Nov; 57(5):385-91. PubMed ID: 8564802
[TBL] [Abstract][Full Text] [Related]
7. Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 metabolism in calcium-deficient rats.
Matsumoto T; Ikeda K; Yamato H; Morita K; Ezawa I; Fukushima M; Nishii Y; Ogata E
Biochem J; 1988 Mar; 250(3):671-7. PubMed ID: 2839142
[TBL] [Abstract][Full Text] [Related]
8. 1alpha-hydroxyvitamin D2 partially dissociates between preservation of cancellous bone mass and effects on calcium homeostasis in ovariectomized rats.
Erben RG; Bante U; Birner H; Stangassinger M
Calcif Tissue Int; 1997 May; 60(5):449-56. PubMed ID: 9115163
[TBL] [Abstract][Full Text] [Related]
9. 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients.
Mortensen BM; Aarseth HP; Ganss R; Haug E; Gautvik KM; Gordeladze JO
Bone; 1993; 14(2):125-31. PubMed ID: 8334029
[TBL] [Abstract][Full Text] [Related]
10. Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice.
Ecarot B; Glorieux FH; Desbarats M; Travers R; Labelle L
J Bone Miner Res; 1995 Mar; 10(3):424-31. PubMed ID: 7785464
[TBL] [Abstract][Full Text] [Related]
11. 1,25 dihydroxyvitamin D3 alone or in combination with parathyroid hormone does not increase bone mass in young rats.
Gunness-Hey M; Gera I; Fonseca J; Raisz LG; Hock JM
Calcif Tissue Int; 1988 Nov; 43(5):284-8. PubMed ID: 3145794
[TBL] [Abstract][Full Text] [Related]
12. Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults.
Vaes AMM; Tieland M; de Regt MF; Wittwer J; van Loon LJC; de Groot LCPGM
Clin Nutr; 2018 Jun; 37(3):808-814. PubMed ID: 28433267
[TBL] [Abstract][Full Text] [Related]
13. Mineral metabolism in obese children.
Zamboni G; Soffiati M; Giavarina D; Tató L
Acta Paediatr Scand; 1988 Sep; 77(5):741-6. PubMed ID: 2849283
[TBL] [Abstract][Full Text] [Related]
14. Effect of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 maternal loads on maternal and fetal vitamin D metabolite levels in the rat.
Rebut-Bonneton C; Demignon J; Cancela L; Miravet L
Reprod Nutr Dev (1980); 1985; 25(3):583-90. PubMed ID: 3875130
[TBL] [Abstract][Full Text] [Related]
15. Chlorpromazine alters bone metabolism of rats in vivo.
Komoda T; Nagata A; Kiyoki M; Miura M; Koyama I; Sakagishi Y; Kumegawa M
Calcif Tissue Int; 1988 Jan; 42(1):58-62. PubMed ID: 2834031
[TBL] [Abstract][Full Text] [Related]
16. The effect of vitamin D on bone in vivo.
Tam CS; Heersche JN; Jones G; Murray TM; Rasmussen H
Endocrinology; 1986 Jun; 118(6):2217-24. PubMed ID: 3486118
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D status in Paget's bone disease. Effects of calcitonin therapy.
Nunziata V; Giannattasio R; di Giovanni G; Lettera AM; Nunziata CA
Clin Orthop Relat Res; 1993 Aug; (293):366-71. PubMed ID: 8339504
[TBL] [Abstract][Full Text] [Related]
18. Effect of the X-linked Hyp mutation and vitamin D status on induction of renal 25-hydroxyvitamin D3-24-hydroxylase.
Tenenhouse HS; Jones G
Endocrinology; 1987 Feb; 120(2):609-16. PubMed ID: 3803293
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] metabolism in vitamin D-deficient rats infused with 1,25-(OH)2D3.
Yamato H; Matsumoto T; Fukumoto S; Ikeda K; Ishizuka S; Ogata E
Endocrinology; 1989 Jan; 124(1):511-7. PubMed ID: 2783309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
